Intravitreal bevacizumab in diabetic retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 knobloch lecture

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

7 Citas (Scopus)

Resumen

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy.

Idioma originalInglés estadounidense
Páginas (desde-hasta)36-39
Número de páginas4
PublicaciónAsia-Pacific Journal of Ophthalmology
Volumen7
N.º1
DOI
EstadoPublicada - ene 1 2018

All Science Journal Classification (ASJC) codes

  • Oftalmología

Citar esto